Resilience in animal healthcare
Two of AIM’s animal healthcare businesses issued positive updates which we reflect on here. Despite evident progress, the shares of one remain under the cloud of a government review into the sector. Elsewhere in the medical world there was disappointing news for shareholders in one early stage medical device company - it's certainly tough for early-stage businesses to develop in the glare of public markets. Read on here for our thoughts on this and oither news. (Premium)
Client portfolios managed by our associates, AIM investing specialists Fundamental Asset Management, may hold shares in companies covered here.Animalcare: another sale to private equity, but at least AIM is left with something Animalcare Group (AIM:ANCR), the international animal health business, has sold a non-core division for a very attractive price. Its majority shareholding in Identicare has been sold to private equity group Bridgepoint for £24.9m. For the 12 months to 31 December 2023, Identicare generated a profit before tax of approximately £0.1m, so they appear to have achieved a very good price, based on that simple measure at least. Identicare is…